Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated?

Research output: Contribution to journalJournal articlepeer-review

Standard

Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated? / Nordsborg, Nikolai Baastrup; Bonne, Thomas Christian; Breenfeldt Andersen, Andreas; Sørensen, Henrik; Bejder, Jacob.

In: Medicine and Science in Sports and Exercise, Vol. 55, No. 7, 2023, p. 1334-1341.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Nordsborg, NB, Bonne, TC, Breenfeldt Andersen, A, Sørensen, H & Bejder, J 2023, 'Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated?', Medicine and Science in Sports and Exercise, vol. 55, no. 7, pp. 1334-1341. https://doi.org/10.1249/MSS.0000000000003156

APA

Nordsborg, N. B., Bonne, T. C., Breenfeldt Andersen, A., Sørensen, H., & Bejder, J. (2023). Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated? Medicine and Science in Sports and Exercise, 55(7), 1334-1341. https://doi.org/10.1249/MSS.0000000000003156

Vancouver

Nordsborg NB, Bonne TC, Breenfeldt Andersen A, Sørensen H, Bejder J. Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated? Medicine and Science in Sports and Exercise. 2023;55(7):1334-1341. https://doi.org/10.1249/MSS.0000000000003156

Author

Nordsborg, Nikolai Baastrup ; Bonne, Thomas Christian ; Breenfeldt Andersen, Andreas ; Sørensen, Henrik ; Bejder, Jacob. / Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated?. In: Medicine and Science in Sports and Exercise. 2023 ; Vol. 55, No. 7. pp. 1334-1341.

Bibtex

@article{d4f1802e268f41968050c48c7a6b68c7,
title = "Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated?",
abstract = "Purpose: The World Anti-Doping Agency prohibit glucocorticoid administration in-competition but not in periods out-of-competition. Glucocorticoid usage is controversial as it may improve performance, albeit debated. A hitherto undescribed but performance relevant effect of glucocorticoids in healthy humans is accelerated erythropoiesis. We investigated whether a glucocorticoid injection accelerate erythropoiesis, increase total hemoglobin mass, and improve exercise performance.Methods: In a counterbalanced, randomized, double-blinded, placebo-controlled crossover design (3-months washout), ten well-trained males (peak oxygen uptake: 60 ± 3 mL O2·min-1·kg-1) were injected with 40 mg triamcinolone acetonide (glucocorticoid group) or saline (placebo group) in the gluteal muscles. Venous blood samples collected before and 7-10 h, 1, 3, 7, 14 and 21 days after treatment were analyzed for hemoglobin concentration and reticulocyte percentage. Hemoglobin mass and mean power output in a 450-kcal time trial was measured before as well as one and three weeks after treatment.Results: A higher reticulocyte percentage was evident three (19 ± 30 %, P < 0.05) and seven (48 ± 38 %, P < 0.001) days after glucocorticoid administration, compared with placebo, whereas hemoglobin concentration was similar between groups. Additionally, hemoglobin mass was higher (P < 0.05) seven (glucocorticoid: 886 ± 104 g, placebo: 872 ± 103 g) and 21 days (glucocorticoid: 879 ± 111 g, placebo: 866 ± 103 g) after glucocorticoid administration compared with placebo. Mean power output was similar between groups seven (glucocorticoid: 278 ± 64 W, placebo: 275 ± 62 W) and 21 days (glucocorticoid: 274 ± 62 W, placebo: 275 ± 60 W) after treatment.Conclusions: Intramuscular injection of 40 mg triamcinolone acetonide accelerates erythropoiesis and increase hemoglobin mass but does not improve aerobic exercise performance in the present study. The results are important for sport physicians administering glucocorticoids and prompt a reconsideration of glucocorticoid usage in sport.",
keywords = "Faculty of Science, Corticosteroid, Reticulocytes, Antidoping, Exercise, Therapeutic use exemption",
author = "Nordsborg, {Nikolai Baastrup} and Bonne, {Thomas Christian} and {Breenfeldt Andersen}, Andreas and Henrik S{\o}rensen and Jacob Bejder",
note = "Copyright {\textcopyright} 2023 by the American College of Sports Medicine.",
year = "2023",
doi = "10.1249/MSS.0000000000003156",
language = "English",
volume = "55",
pages = "1334--1341",
journal = "Medicine and Science in Sports and Exercise",
issn = "0195-9131",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Glucocorticoids accelerate erythropoiesis in healthy humans - should the use in sports be reevaluated?

AU - Nordsborg, Nikolai Baastrup

AU - Bonne, Thomas Christian

AU - Breenfeldt Andersen, Andreas

AU - Sørensen, Henrik

AU - Bejder, Jacob

N1 - Copyright © 2023 by the American College of Sports Medicine.

PY - 2023

Y1 - 2023

N2 - Purpose: The World Anti-Doping Agency prohibit glucocorticoid administration in-competition but not in periods out-of-competition. Glucocorticoid usage is controversial as it may improve performance, albeit debated. A hitherto undescribed but performance relevant effect of glucocorticoids in healthy humans is accelerated erythropoiesis. We investigated whether a glucocorticoid injection accelerate erythropoiesis, increase total hemoglobin mass, and improve exercise performance.Methods: In a counterbalanced, randomized, double-blinded, placebo-controlled crossover design (3-months washout), ten well-trained males (peak oxygen uptake: 60 ± 3 mL O2·min-1·kg-1) were injected with 40 mg triamcinolone acetonide (glucocorticoid group) or saline (placebo group) in the gluteal muscles. Venous blood samples collected before and 7-10 h, 1, 3, 7, 14 and 21 days after treatment were analyzed for hemoglobin concentration and reticulocyte percentage. Hemoglobin mass and mean power output in a 450-kcal time trial was measured before as well as one and three weeks after treatment.Results: A higher reticulocyte percentage was evident three (19 ± 30 %, P < 0.05) and seven (48 ± 38 %, P < 0.001) days after glucocorticoid administration, compared with placebo, whereas hemoglobin concentration was similar between groups. Additionally, hemoglobin mass was higher (P < 0.05) seven (glucocorticoid: 886 ± 104 g, placebo: 872 ± 103 g) and 21 days (glucocorticoid: 879 ± 111 g, placebo: 866 ± 103 g) after glucocorticoid administration compared with placebo. Mean power output was similar between groups seven (glucocorticoid: 278 ± 64 W, placebo: 275 ± 62 W) and 21 days (glucocorticoid: 274 ± 62 W, placebo: 275 ± 60 W) after treatment.Conclusions: Intramuscular injection of 40 mg triamcinolone acetonide accelerates erythropoiesis and increase hemoglobin mass but does not improve aerobic exercise performance in the present study. The results are important for sport physicians administering glucocorticoids and prompt a reconsideration of glucocorticoid usage in sport.

AB - Purpose: The World Anti-Doping Agency prohibit glucocorticoid administration in-competition but not in periods out-of-competition. Glucocorticoid usage is controversial as it may improve performance, albeit debated. A hitherto undescribed but performance relevant effect of glucocorticoids in healthy humans is accelerated erythropoiesis. We investigated whether a glucocorticoid injection accelerate erythropoiesis, increase total hemoglobin mass, and improve exercise performance.Methods: In a counterbalanced, randomized, double-blinded, placebo-controlled crossover design (3-months washout), ten well-trained males (peak oxygen uptake: 60 ± 3 mL O2·min-1·kg-1) were injected with 40 mg triamcinolone acetonide (glucocorticoid group) or saline (placebo group) in the gluteal muscles. Venous blood samples collected before and 7-10 h, 1, 3, 7, 14 and 21 days after treatment were analyzed for hemoglobin concentration and reticulocyte percentage. Hemoglobin mass and mean power output in a 450-kcal time trial was measured before as well as one and three weeks after treatment.Results: A higher reticulocyte percentage was evident three (19 ± 30 %, P < 0.05) and seven (48 ± 38 %, P < 0.001) days after glucocorticoid administration, compared with placebo, whereas hemoglobin concentration was similar between groups. Additionally, hemoglobin mass was higher (P < 0.05) seven (glucocorticoid: 886 ± 104 g, placebo: 872 ± 103 g) and 21 days (glucocorticoid: 879 ± 111 g, placebo: 866 ± 103 g) after glucocorticoid administration compared with placebo. Mean power output was similar between groups seven (glucocorticoid: 278 ± 64 W, placebo: 275 ± 62 W) and 21 days (glucocorticoid: 274 ± 62 W, placebo: 275 ± 60 W) after treatment.Conclusions: Intramuscular injection of 40 mg triamcinolone acetonide accelerates erythropoiesis and increase hemoglobin mass but does not improve aerobic exercise performance in the present study. The results are important for sport physicians administering glucocorticoids and prompt a reconsideration of glucocorticoid usage in sport.

KW - Faculty of Science

KW - Corticosteroid

KW - Reticulocytes

KW - Antidoping

KW - Exercise

KW - Therapeutic use exemption

U2 - 10.1249/MSS.0000000000003156

DO - 10.1249/MSS.0000000000003156

M3 - Journal article

C2 - 36878016

VL - 55

SP - 1334

EP - 1341

JO - Medicine and Science in Sports and Exercise

JF - Medicine and Science in Sports and Exercise

SN - 0195-9131

IS - 7

ER -

ID: 338348472